Diagnostics Pipeline: To Gain Insight into Haystack MRD Test, Quest Works with City of Hope
New liquid biopsy assay will be used in conjunction with 500 cancer patients currently enrolled in clinical trials
Already a member? Log in here
Diagnostic Testing and Emerging Technologies
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
Quest Diagnostics Launches Consumer-Facing AI on Its App and Portal
The company’s patients can use AI to look at trends going back five years
Already a member? Log in here
Thermo Fisher Scientific Debuts Pharmacogenetic Test to Improve Transplant Safety
Proper dosing helps prevent potential side effects such as developing diabetes and kidney damage
Already a member? Log in here
AI: With the Lab Every Step of the Way
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
Already a member? Log in here
Profiling Pathogens for Public Health
Genomic epidemiology can provide insights into pathogen transmission and evolution—and facilitate better countermeasures against infectious disease.
Already a member? Log in here
The Diagnostics Pipeline: FDA Approves First Ever Fentanyl Test Strips for OTC Use
Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Already a member? Log in here
A 21st Century Response to the Cures Act
Patients’ unfettered access to complex test results can lead to confusion and distress—but generative AI can help.
Already a member? Log in here
Expert Q&A: What’s Next in Next-Generation Sequencing?
Crystal Girod, MSc, of Beckman Coulter Life Sciences discusses recent developments in NGS and their impact on clinical diagnostics.
Already a member? Log in here
FDA’s LDT Proposal Raises Questions About Clinical Validity
Debate is underway on whether current CLIA review of LDTs properly assesses a test’s likelihood to detect diseases.
Already a member? Log in here
Expert Q&A: Key Developments in AI and Digital Pathology
Juan Antonio Retamero, MD, shares his thoughts on recent trends in AI and digital pathology, and how they may progress.
Already a member? Log in here
The Diagnostics Pipeline: FDA Moves to Modernize 510(k) Process for New Lab Tests & Devices
The changes proposed in three new draft guidances aim to speed up the process and place less emphasis on older predicate products.
Already a member? Log in here
Expert Q&A: Challenges in Pathology and Potential Solutions
Liron Pantanowitz, MD, PhD, discusses the key issues pathologists face today, and how technology could help.
Already a member? Log in here
Seeing Past the AI Hype
Artificial intelligence won’t take your job—but what are the real concerns around healthcare AI and its use?
Already a member? Log in here
